Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1956-1962

  Chan, Kevin ^a   Moran, John ^b   Hlatky, Mark ^c   Lafayette, Richard ^a  

^a Department of Nephrology ^*  (United States)

^b University of Minnesota   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaemia management; ESRD; Processes of care

Indexed keywords

FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG DOSE TITRATION; DRUG UTILIZATION; EVALUATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; RISK;

AGED; ANEMIA; CLINICAL PROTOCOLS; COHORT STUDIES; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 67651085464     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn780     Document Type: Article

References (29)

1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease. Kidney Int 1985; 28: 1-5
2. Steinbrook R. Medicare and erythropoietin. NEJM 2007; 356: 4-6
3. Ofsthun N, Labrecque J, Lacson E. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914
4. Macdougall IC, Coles GA, Williams JD et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489-493
5. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
6. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
7. Collins AJ, Brenner RM, Ofman JJ et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. AmJKidneyDis 2005; 46: 481-488
8. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
9. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
10. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporespon-siveness in maintenance hemodialysis patients. AmJKidneyDis 2003; 42: 761-773
11. Brimble KS, Rabbat CG, McKenna P et al. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 2003; 14: 2654-2661
12. Eschbach J, DeOreo P, Adamson J et al. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure Am J Kidney Dis 1997; 30: S192-S240
13. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD AmJKidneyDis 2003; 41: 111-124
14. Chan K, Lafayette RA, Whittemore AS et al. Facility factors dominate the ability to achieve target hemoglobin levels in hemodialysis patients. Nephrol Dial Transplant 2008; 23: 2948-2956
15. Fink JC, Hsu VD, Zhan M et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: 646-653
16. Reddan DN, Frankenfield DL, Klassen PS et al. Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant 2003; 18: 147-152
17. Krishnan M, Adams E. Operationalizing anemia management: organizing the program and coordinating the team. Nephrol Nurs J 2003; 30: 567-570
18. Hossli S. Developing an anemia management protocol. Case study of the anemic patient. ANNA J 1997; 24: 678-684
19. Drüeke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16(S7): 25-28
20. Messana T. Erythropoietin claims monitoring policy: implications for clinical practice. Nephrol Nurs J 2006; 33: 209-222
21. The Medicare Payment Advisory Commission. Improving the quality of care for beneficiaries with end-stage renal disease. 1999 (available www.medpac.gov/publications/congressional-reports/Jun99%20Ch8.pdf)
22. Yang W, Rubeen K, Israni et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170
23. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models Biometrika 1986; 73: 13-22
24. Barany P, Muller H.-J. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 10-18
25. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl JMed 2006; 355: 2071-2084
26. Phrommintikul A, Haas SJ, Maros E et al. Mortality and target hemoglobin concentration in anemic patients with chronic kidney disease treated with erythropoietin: a meta analysis. Lancet 2007; 369: 381-388
27. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
28. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl JMed 2006; 355: 2071-2084
29. Weiner DE, Miskulin DC, Seefield K et al. Reducing versus dis-continuing erythropoietin at high hemoglobin levels. JASN 2007; 18: 3184-3191